Iradimed (NASDAQ:IRMD) Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Iradimed (NASDAQ:IRMD) announced its quarterly earnings results on Thursday. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.05), Zacks reports. The business had revenue of $19,390 billion during the quarter, compared to the consensus estimate of $19.20 million. Iradimed had a net margin of 26.12% and a return on equity of 23.99%. Iradimed updated its Q1 2025 guidance to 0.390-0.430 EPS and its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Price Performance

Shares of IRMD traded down $0.17 during trading hours on Friday, hitting $55.23. The stock had a trading volume of 51,661 shares, compared to its average volume of 36,478. The company’s fifty day moving average is $57.20 and its two-hundred day moving average is $52.10. Iradimed has a 52 week low of $40.18 and a 52 week high of $63.29. The stock has a market capitalization of $699.76 million, a price-to-earnings ratio of 37.83 and a beta of 0.82.

Iradimed Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 5th. Stockholders of record on Monday, February 24th will be issued a $0.17 dividend. This is a positive change from Iradimed’s previous quarterly dividend of $0.15. The ex-dividend date is Monday, February 24th. This represents a $0.68 annualized dividend and a dividend yield of 1.23%. Iradimed’s dividend payout ratio is presently 41.10%.

Analyst Upgrades and Downgrades

IRMD has been the topic of several analyst reports. Roth Mkm reissued a “buy” rating and issued a $72.00 price target (up previously from $60.00) on shares of Iradimed in a report on Friday. StockNews.com lowered shares of Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Insiders Place Their Bets

In other Iradimed news, CFO John Glenn sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now owns 4,383 shares in the company, valued at approximately $237,470.94. This trade represents a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.